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Abstract Missense mutations in ATP1A3 encoding Na+,K+-
ATPase α3 are the primary cause of alternating hemiplegia of
childhood (AHC). Most ATP1A3mutations in AHC lie within
a cluster in or near transmembrane α-helix TM6, including
I810N that is also found in theMyshkinmouse model of AHC.
These mutations all substantially reduce Na+,K+-ATPase α3
activity. Herein, we show that Myshkin mice carrying a wild-
type Atp1a3 transgene that confers a 16 % increase in brain-
specific total Na+,K+-ATPase activity show significant pheno-
typic improvements compared with non-transgenic Myshkin
mice. Interventions to increase the activity of wild-type Na+,
K+-ATPase α3 in AHC patients should be investigated
further.
Keywords Alternating hemiplegia . Transgenic rescue .
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Introduction
Alternating hemiplegia of childhood (AHC; OMIM: 614820)
is a rare neurodevelopmental disorder which manifests as ep-
isodic hemiplegia starting in the first 18 months of life, with a
spectrum of persistent motor, movement, and cognitive defi-
cits that become progressively more apparent with age [1, 2].
Approximately half of AHC patients present with epilepsy;
the seizures are predominantly partial but may manifest as
status epilepticus requiring urgent medical attention [2]. Het-
erozygous missense mutations of the ATP1A3 gene, encoding
the Na+,K+-ATPase α3 subunit, have been identified as the
primary cause of AHC [3]. Belonging to the type II P-type
ATPase family of proteins that have a transmembrane domain
permeable to specific ions, Na+,K+-ATPases are membrane-
bound transporters that harness the energy of ATP hydrolysis
to pump three Na+ ions out of the cell in exchange for two K+
ions moving inward [4]. The α3 subunit has ten transmem-
brane α-helices which contain the Na+- and K+-binding sites
and the cytoplasmic domains involved in ATP hydrolysis [4].
Most ATP1A3 mutations in AHC patients lie within a cluster
in or near transmembrane α-helix TM6 [5], including three
affecting the isoleucine at position 810: I810F [5], I810N [6],
and I810S [7]. Flunarizine, a non-selective calcium entry
blocker targeting voltage-dependent calcium channels, re-
duces the severity, duration, or frequency of hemiplegic at-
tacks in some patients [6], while two AHC patients—positive
for T804I and D923N, respectively—have shown marked im-
provements in symptoms when treated with a ketogenic diet
[8, 9]. However, the complexity and severity of AHC make it
imperative that new therapeutic options specifically targeting
Na+,K+-ATPase α3 be explored.
To better understand the consequences of Na+,K+-ATPase
α3 dysfunction and explore potential therapeutic approaches
for this disorder, investigations in animal models harboring
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the same mutations as human patients are needed. Heterozy-
gous Myshkin (Atp1a3Myk/+; Myk/+) mutant mice have an
I810N amino acid substitution in transmembrane α-helix
TM6 identical to that present in AHC [6, 10]. A 12-year-old
Chinese male with the I810N mutation is reported to have
AHC with developmental delay and epilepsy [6].Myk/+ mice
often show hypokinesia upon arousal and move with a paretic,
tremulous gait that becomes transiently more severe after
stress (Supplementary Video 1 and 2) [11]. Myk/+ mice have
not, however, been observed by video monitoring over 24 h,
so it is not known whether they exhibit frank hemiparesis or
hemiplegia when left undisturbed in the home cage. Other
phenotypic abnormalities include decreased body mass, neu-
ronal hyperexcitability, increased susceptibility to epileptic
seizures, motor dysfunction, and cognitive impairment
[10–12]. Molecular modeling of I810N has shown that it
brings about severe structural effects on Na+,K+-ATPase α3,
including the capacity for efficient K+movement along the K+
access pathway [11].
Missense mutations in AHC patients and Myk/+ mice all
substantially reduce Na+,K+-ATPase α3 activity [8, 13].
I810N in Myk/+ mice is functionally a null allele of Atp1a3
that encodes a normally expressed, but catalytically inactive,
Na+,K+-ATPase α3 enzyme [8]. Brain-specific total Na+,K+-
ATPase activity (contributed by α1, α2, and α3 isoforms) is
64% ofwild-type levels inMyk/+mice [14], but 84% ofwild-
type levels in heterozygous Atp1a3tm1Ling/+ mice that have a
point mutation in intron 4 of the Atp1a3 gene [14, 15]. Since
Atp1a3tm1Ling/+ mice do not have visible neurological defects
nor restricted growth [15], we hypothesized that increasing
brain Na+,K+-ATPase activity from 64 % to closer to 84 %
of wild-type levels would mitigate disease phenotype severity
in Myk/+ mice.
Transgenic (Tg)-Atp1a31Stclmice carry a bacterial artificial
chromosome (BAC) transgene of Mus musculus molossinus
origin (MSMg01-344N17) that contains the wild-type Atp1a3
gene and its promoter [10]. The Tg-Atp1a31Stcl transgene was
previously shown to increase Na+,K+-ATPase α3 protein ex-
pression by 58 % and brain Na+,K+-ATPase activity from 64
to 80 % of wild-type levels in Myk/+ mice [10]. The purpose
of the present study was to determine whether this increase in
brain Na+,K+-ATPase activity, to a level comparable with that
of Atp1a3tm1Ling/+ mice (~80 % of wild-type), would have
remedial effects in phenotypic tests in which Myk/+ mice
show clear deficiencies.
Materials and methods
Subjects
Myk/+ mice were genotyped by the presence of an EcoO109I
(New England BioLabs) restriction site using PCR primers F,
5′-CTG CCG GAA ATA CAA TAC TGA-3′ and R, 5′-ATA
AAT ACC CCA CCA CTG AGC-3′. Hemizygous Tg-
Atp1a31Stcl/+ (Tg/+) mice were genotyped using PCR primers
F, 5′-TGA CAT TGT AGG ACT ATA TTG C-3′ and R, 5′-
GTT AAA GGT GTG AGG CAC AGA-3′ spanning the T7
vector-insert boundary. Both lines were backcrossed for 11
(Tg/+) or 21 generations (Myk/+) to the C57BL/6NCr strain
(NCI-Frederick). Myk/+ males were crossed with Tg/+ fe-
males to yield wild-type (+/+), Myk/+, Tg/+, and Myk/+/Tg
(I810N + Tg-Atp1a31Stcl) littermates. Mice were weaned at
4 weeks of age and grouped housed (two to five mice/cage)
with same-sex littermates. Supplementary food pellets were
provided on the cage floor for the first 2 weeks post-
weaning because of the small size of Myk/+ mice. Mice were
weighed at 4 and 8 weeks of age using a Scout Pro portable
balance (Ohaus).
Behavioral procedures
Myk/+, +/+, Tg/+, andMyk/+/Tg littermates (n=12/genotype)
were tested at 8–14 weeks of age. Males and females were
included in balanced numbers. Subjects were handled daily
for 5 min/day for 7 days prior to behavioral testing, which was
conducted during the light phase (0900–1700 h). Prior to ex-
periments, subjects were left undisturbed in the testing envi-
ronment for 30 min to allow for acclimation. A solution of
70 % ethanol was used to clean surfaces and equipment be-
tween subjects. The order of tests, with a rest period of 3–
5 days between each test, was as follows: body weight →
balance beam→Morris water maze→ fear conditioning.
Balance beam
Mice were given five training trials on a 90-cm-long, 18-mm-
wide beam elevated 50 cm above a padded base. A 60-W
lamp at the start platform served as an aversive stimulus,
whereas the opposite end of the beam entered a darkened
escape box baited with food pellets. Performance on the beam
was quantified in a test trial given 24 h after training by mea-
suring the time that it took for the mouse to traverse the beam
and the number of hind foot slips that occurred in the process.
Visible platform water maze
The water maze consisted of a cylindrical tub of ivory-colored
acrylic sheet (117-cm diameter; 30-cm depth) that was filled
with water (26±1 °C temperature) to 11 cm below the rim. A
circular platform (10-cm diameter) made of transparent acrylic
sheet was submerged 1 cm below the water surface at the
center of the pool. The platform location was indicated by a
high-contrast striped marker rising 13 cm above the water
surface. Each subject was given four training trials. At the start
of each trial, the mouse was placed by the tail into the water,
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immediately facing the perimeter, at one of the cardinal com-
pass points (north, south, east, or west), and then was allowed
a maximal time of 90 s to locate the platform. Finding the
platform was defined as staying on it for at least 2 s. A
closed-circuit television camera was mounted onto the ceiling
directly above the center of the pool to convey subject swim-
ming trajectories and parameters to an electronic image ana-
lyzer (HVS Image), which extracted and stored the X-Y coor-
dinates of the subject’s position at sample points every 0.01 s.
Behavioral variables were quantified with the aid of HVS
Water 2020 (HVS Image).
Contextual fear conditioning
Experiments were conducted in a fear-conditioning chamber
(MED Associates; 25-cm height×30-cm width×25-cm
length) with a removable grid floor of 36 stainless steel rods
(3.2-mm diameter, 4.7 mm apart) connected to a constant
current shock generator. FreezeFrame 1.6e software
(Actimetrics) administered foot shocks, recorded video im-
ages of the chamber, and monitored the activity of subjects
throughout the procedure. For the training phase, mice were
placed in the chamber for 2 min 28 s, after which, they re-
ceived a continuous scrambled foot shock of 0.75 mA for 2 s
and then remained in the chamber for an additional 30 s before
being returned to their home cage. Twenty-four hours follow-
ing training, mice were returned to the fear-conditioning
chamber to evaluate their contextual fear memory. Freezing
to the context was recorded at 0.25-s intervals using
FreezeFrame for 3 min, and then, mice were returned to their
home cage.
Statistical analysis
All statistics were calculated by STATISTICA (StatSoft). Data
were subjected to analysis of variance (ANOVA) with Atp1a3
genotype, Tg genotype, and sex as between-subjects factors.
No sex by Atp1a3 genotype or sex by Tg genotype interaction
was observed for any variable measured. When ANOVA de-
tected statistically significant main effects, pairwise differ-
ences were evaluated using Tukey-Kramer post hoc multiple
comparison tests, with significance set at p<0.05. Student’s
paired t test was used to compare baseline freezing with con-
textual freezing. All values reported in the figures are
expressed as mean±standard error of the mean (SEM).
Results and discussion
Body weight
AHC patients tend to be of short stature and low weight [2,
16]. We measured the body weight of mice aged 4 weeks,
when they were weaned, and aged 8 weeks, when behavioral
testing commenced. At both ages, the body weight of Myk/+
mice was significantly less than that of the other genotypes
(Fig. 1). Relative to +/+ mice, the 4-week weight of Myk/+
mice was less by 20.4±5.1 % in females and by 20.6±6.1 %
in males. By 8 weeks, body weight was less by 10.8±3.3 % in
Myk/+ females and by 18.6±3.3 % inMyk/+ males, and a sex
by Atp1a3 genotype interaction approaching significance
(F(1, 42)=3.66, p=0.0626) was observed. Myk/+/Tg mice
did not show any significant deficits in body weight, as con-
firmed by the significant Atp1a3 genotype by Tg genotype
interactions observed (Fig. 1). In a previous study, we found
that the 9-week weight of Myk/+ mice was less by 18.8 % in
males and 16.1 % in females [10]. The smaller deficit of adult
Myk/+ females in the present study could reflect a sex-specific
response to differing husbandry conditions. Male heterozy-
gous Atp1a3D801N/+ mice, which carry the most common mu-
tation causing AHC (D801N), also show lower bodyweight at
8 and 9 weeks of age, but Atp1a3D801N genotype had no effect
on the body weight of female mice at any age [17].
Balance beam
Abnormalities of fine motor skills are present in the vast ma-
jority of AHC patients and become more evident with age [2,
18]. As a measure of motor coordination, we tested mice on a
Fig. 1 Body weight (% of +/+; mean±SEM) of male (n=6/genotype)
and female (n=6/genotype) Myk/+, Myk/+/Tg, and Tg/+ mice at 4 and
8 weeks of age. For body weight at 4 weeks, main effects of Atp1a3
genotype (F(1, 42)=8.41, p<0.01), sex (F(1, 42)=7.40, p<0.01), and
Atp1a3 genotype by Tg genotype interaction (F(1, 42)=12.69,
p<0.001) were observed. For body weight at 8 weeks, main effects of
Atp1a3 genotype (F(1, 42)=14.18, p<0.001), Tg genotype (F(1, 42)=
8.84, p<0.01), sex (F(1, 42)=82.72, p<0.0001), and Atp1a3 genotype by
Tg genotype interaction (F(1, 42)=10.83, p<0.01) were observed.
*p<0.05; **p<0.01; ***p<0.001 compared with +/+ mice
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balance beam, which is useful for detecting subtle deficits in
motor skills and balance that may not be detected by other
motor tests, such as the rotarod [19]. At 24 h after training,
Myk/+ mice showed a significantly greater number of hind
foot slips than the other genotypes as they traversed the beam
(Fig. 2a). Myk/+ mice also took longer than the other geno-
types to traverse the beam (Fig. 2b). By contrast, the number
of foot slips and the traversal time ofMyk/+/Tg mice were not
significantly different from those of +/+ mice, as confirmed by
the significant Atp1a3 genotype by Tg genotype interactions
observed (Fig. 2). Atp1a3D801N/+ mice have also performed
poorly in the balance beam test [17].
Visible platform water maze
Cognitive impairment has been observed in 94 % [2] and
100 % [1] of different AHC patient cohorts studied. The
visible platform version of the water maze is a simple associa-
tive non-spatial task believed to be independent of hippocam-
pal function [20]. This procedure introduces the mice to the
main task requirements (e.g., swimming, the fact that the plat-
form is not near the perimeter, and climbing on the platform to
escape) and assesses whether they have the performance skills
necessary for spatial memory to be assessed in the hidden
platform task. In this rather stressful condition, mice are re-
quired to maintain sufficient behavioral flexibility to over-
come their initial tendency to swim along the wall of the pool,
an innate behavior called wall hugging or thigmotaxis [20].
Then, they must learn that they are returned to their warm
home cage if they climb and stay on the escape platform
indicated by a marker rising above the water.
Over four trials, only +/+ and Tg/+ mice showed quick
orientation toward the visually marked platform location.
Myk/+ andMyk/+/Tg mice took more time (Fig. 3a) and swam
further (Fig. 3b) before reaching the visible platform. Myk/+/
Tgmice performed marginally better thanMyk/+ mice, but the
overall performance of both was poor, as confirmed by the
lack of Atp1a3 genotype by Tg genotype interactions for la-
tency and path length. There were no significant differences
between genotypes in swim speed and floating. The deficient
performances of Myk/+ and Myk/+/Tg mice were largely due
to their excessive thigmotaxis (Fig. 3c), an effect of the I810N
mutation not attenuated by the Atp1a31Stcl transgene. The mu-
tation reduced behavioral flexibility to such a degree that
Myk/+ and Myk/+/Tg mice were practically unable to over-
come thigmotaxis, as previously observed in mice with
forebrain-specific knockout of the TrkB receptor [22]. Exces-
sive thigmotaxis has also been observed in mice with retinal
degeneration [23], but the normal head tracking of Myk/+
mice in an optokinetic drum suggests that their vision is not
impaired [14].
Atp1a3D801N/+ mice have also performed poorly in the vis-
ible platform task [17]. Atp1a3tm1Ling/+ mice were given four
trials per day for 6 days, in which the visible platform position
was changed at random on each trial. Atp1a3tm1Ling/+ mice
took significantly longer to reach the visible platform on days
2–5 but caught up to wild-type controls by day 6 [15].
Contextual fear conditioning
Contextual fear conditioning assesses a memory for the asso-
ciation between an aversive stimulus, such as a mild foot
shock, and a salient environmental cue, the test chamber
(Bcontext^). Rodents with good memory have a natural ten-
dency to freeze (suppress all movement) upon re-presentation
of the context. Contextual fear conditioning is dependent upon
the integrity of the hippocampus [24]. Baseline freezing, be-
fore the administration of a foot shock, was less than 3 % for
all genotypes, although the baseline freezing of Tg/+ micewas
significantly greater than that of +/+ andMyk/+ mice (Fig. 3d).
Fig. 2 Balance beam performance of +/+, Myk/+, Myk/+/Tg, and Tg/+
mice (n=12/genotype). a Number of hind foot slips (mean±SEM) and b
traversal time (s; mean±SEM) when traversing a narrow beam. For the
number of foot slips, main effects of Atp1a3 genotype (F(1, 42)=14.11,
p<0.001) and Atp1a3 genotype by Tg genotype interaction (F(1, 42)=
5.02, p<0.05) were observed. For traversal time, main effects of Atp1a3
genotype (F(1, 42)=22.19, p<0.0001), Tg genotype (F(1, 42)=5.52,
p<0.05), and Atp1a3 genotype by Tg genotype interaction (F(1, 42)=
9.54, p<0.01) were observed. ***p<0.001; ****p<0.0001 compared
with +/+ mice
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At 24 h after receiving the foot shock, all genotypes increased
their level of freezing compared with baseline, butMyk/+mice
showed a significantly lower level of contextual freezing than
the other genotypes. By contrast,Myk/+/Tg mice did not show
any deficit in contextual fear conditioning, as confirmed by
the significant Atp1a3 genotype by Tg genotype interaction
observed (Fig. 3d). Unlike Myk/+ mice, Atp1a3D801N/+ mice
have not shown any deficit in the formation of fear-related
memories in the contextual fear-conditioning paradigm [17].
The clinical severity of AHC is extremely variable, but the
rarity of the disorder has made it difficult to study genotype-
phenotype correlations. Nevertheless, the high frequency of
D801N and E815K, responsible for most AHC cases, has
allowed two independent studies to show that E815K causes
a more severe phenotype than D801N with respect to age of
onset, motor impairment, and a prevalence of status epilepticus
[25, 26]. Differences in mutant enzyme activity cannot account
for the disease severity associated with E815K, since all of the
AHC mutations that have been studied to date—S137Y,
I274N, D801N, I810N, E815K, and G947R—were found to
result in a catalytically inactive α3 enzyme [10, 13]. However,
the recent finding that E815K, but not D801N and G947R,
impairs the passive influx of protons into the cell [27] suggests
that loss of proton transport is a correlate of severe AHC [28].
The isoleucine at position 810 is recurrently mutated in
AHC [5–7], but I810N is one of the rarer mutations, having
been found in only two cases to date: a 22-year-old male from
Belgium with clinical features of episodic hemiplegia and dys-
tonia triggered by emotional stress, mild ataxia with unstable
gait, moderate intellectual disability and autism, and a clinical
Fig. 3 Water maze and fear-conditioning performance of +/+, Myk/+,
Myk/+/Tg, and Tg/+ mice (n=12/genotype). a Escape latency (s; mean
±SEM). Main effects of Atp1a3 genotype (F(1, 42)=77.09, p<0.0001)
and Tg genotype (F(1, 42)=7.79, p<0.01) were observed for latency. b
Swim path length (m; mean±SEM). Main effects of Atp1a3 genotype
(F(1, 42)=67.20, p<0.0001) and Tg genotype (F(1, 42)=9.10, p<0.01)
were observed for path length. c Thigmotaxis (% time; mean±SEM).
Main effects of Atp1a3 genotype (F(1, 42)=53.10, p<0.0001) and Tg
genotype (F(1, 42)=4.59, p<0.05) were observed for thigmotaxis. d
Freezing levels (% time; mean±SEM) of mice when test-naïve
(baseline) and when returned to the chamber 24 h after training (context).
For baseline freezing, a main effect of Tg genotype (F(1, 42)=11.60,
p<0.01) was observed. For context freezing, main effects of Atp1a3 ge-
notype (F(1, 42)=5.33, p<0.05), Tg genotype (F(1, 42)=7.40, p<0.01),
and Atp1a3 genotype by Tg genotype interaction (F(1, 42)=10.01,
p<0.01) were observed. **p<0.01; ***p<0.001; ****p<0.0001 com-
pared with +/+ mice. †p<0.05 compared with Myk/+ mice. ##p<0.01;
####p<0.0001 compared with baseline freezing for each genotype. n.s.
not significant
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history of epilepsy with some episodes of status epilepticus
[29]; and a 12-year-old Chinese male with clinical features of
episodic hemiplegia, quadriplegia, abnormal eye movement,
dystonia, epilepsy, and developmental delay [6].
Haploinsufficiency of ATP1A2 encoding the Na+,K+-
ATPase α2 subunit is associated with familial hemiplegic mi-
graine type 2 [30], but recent functional analysis of α3 sub-
units suggests that an additional dominant-negative mecha-
nism would contribute to loss of function in AHC [28]. Co-
expression of wild-type and mutant α3 subunits (D801N,
E815K, and G947R) in Xenopus laevis oocytes showed that
mutant α3 subunits inhibit wild-type α3 function [28]. This
dominant-negative effect may explain why the Tg-Atp1a31Stcl
transgene increased brain Na+,K+-ATPase activity in Myk/+
mice by only 16 % [10]. Nevertheless, we have found that
this modest increase in brain Na+,K+-ATPase activity was
sufficient to rescue the phenotypic deficiencies ofMyk/+ mice
in body weight, motor coordination, and contextual fear con-
ditioning. Increasing brain Na+,K+-ATPase activity to 80% of
wild-type levels did not, however, rescue the deficient perfor-
mance of Myk/+ mice in the visible platform version of the
water maze, which is consistent with the deficient visible plat-
form performance of Atp1a3tm1Ling/+ mice whose brain Na+,
K+-ATPase activity is at 84 % of wild-type levels [14, 15]. In
conclusion, our results show that a relatively small increase in
Na+,K+-ATPase α3 activity has therapeutic effects in a mouse
model of AHC. In light of these findings, interventions to
increase the activity of wild-type Na+,K+-ATPase α3 in
AHC patients should be investigated further.
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